Data gathered: October 7
Alternative Data for CERo Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,938 | Sign up | Sign up | Sign up |
| X Mentions | 3 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 16 | Sign up | Sign up | Sign up |
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
| Price | $5.32 |
| Target Price | Sign up |
| Volume | 31,000 |
| Market Cap | $6.4M |
| Year Range | $4.68 - $42.8 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
CERo Therapeutics’ (CERO) Buy Rating Reaffirmed at D. Boral CapitalSeptember 24 - ETF Daily News |
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose CohortSeptember 22 - GlobeNewswire |
|
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041September 9 - GlobeNewswire |
|
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid LeukemiaSeptember 8 - GlobeNewswire |
|
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)September 5 - GlobeNewswire |
|
 |
Cero Therapeutics receives notice of allowance from USPTO for CER-1236September 9 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 0 | 0 | -5.4M | -5.2M | -61.710 |
| Q1 '25 | 1.2M | 270,000 | -270,000 | -5.1M | -4.8M | -31.800 |
| Q4 '24 | 0 | 0 | 0 | 0 | 0 | -17.492 |
| Q3 '24 | 0 | 300,000 | -300,000 | -4.2M | -4.4M | -170.223 |
| Q2 '24 | 0 | 290,000 | -290,000 | -2.4M | -2.4M | -302.323 |
Insider Transactions View All
| YK Bioventures Opportunities Fund I, L.P. filed to sell 13,005,169 shares at $0.1. December 13 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 16,004,077 shares at $0.1. December 13 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 17,618,618 shares at $0.1. December 13 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 18,962,419 shares at $0.1. December 10 '24 |
| YK Bioventures Opportunities Fund I, L.P. filed to sell 20,533,366 shares at $0.1. December 10 '24 |
Similar companies
Read more about CERo Therapeutics (CERO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of CERo Therapeutics?
The Market Cap of CERo Therapeutics is $6.4M.
What is the current stock price of CERo Therapeutics?
Currently, the price of one share of CERo Therapeutics stock is $5.32.
How can I analyze the CERO stock price chart for investment decisions?
The CERO stock price chart above provides a comprehensive visual representation of CERo Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling CERo Therapeutics shares. Our platform offers an up-to-date CERO stock price chart, along with technical data analysis and alternative data insights.
Does CERO offer dividends to its shareholders?
As of our latest update, CERo Therapeutics (CERO) does not offer dividends to its shareholders. Investors interested in CERo Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of CERo Therapeutics?
Some of the similar stocks of CERo Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.